Chronic kidney disease (CKD), characterized as renal dysfunction, is recognized as a major
public health problem with high morbidity and mortality worldwide. Unfortunately, there are …

Chronic kidney disease (CKD) represents a major challenge to public healthcare.
Traditional clinical biomarkers of renal function (blood urea nitrogen and serum creatinine) …

Metabolomics—the nontargeted measurement of all metabolites produced by the body—is
beginning to show promise in both biomarker discovery and, in the form of …

Chronic kidney disease (CKD) has emerged as a major public health problem worldwide. It
frequently progresses to end-stage renal disease, which is related to very high cost and …

Diseases of the kidney are difficult to diagnose and treat. This review summarises the
definition, cause, epidemiology and treatment of some of these diseases including chronic …

Diabetic kidney disease (DKD) is one of the most prevalent comorbidities of diabetes
mellitus and the leading cause of the end‐stage renal disease (ESRD). DKD results from …

Chronic kidney disease (CKD) has a high prevalence in the general population and is
associated with high mortality; a need therefore exists for better biomarkers for diagnosis …

The development of new therapies for chronic diseases, such as diabetic kidney disease
(DKD), will continue to be hampered by lack of sufficient biomarkers that will provide insights …

In this review of the application of proteomics and metabolomics to kidney disease research,
we review key concepts, highlight illustrative examples, and outline future directions. The …

The prevalence of chronic kidney disease (CKD) is increasing worldwide, and the mortality
rate continues to be unacceptably high. The biomarkers currently used in clinical practice …